Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of KL1333 (Napazimone) in Patients With Primary Mitochondrial Disease

NCT07514338 is registered in ClinicalTrials.gov with Pharming Technologies B.V. as lead sponsor.

NCT NCT07514338
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07514338 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of KL1333 (Napazimone) in Patients With Primary Mitochondrial Disease
Lead sponsor
Pharming Technologies B.V.
Phase
Phase 2
Overall status
Recruiting
Start date
June 12, 2026
Completion date
March 31, 2029
Enrollment
140 (estimated)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

mitochondrial diseases